-
-
Federal and state funding for family planning client services reached $1.85 billion in FY 2006, a 63% increase over 12 years, adjusting for inflation.
-
A multidrug-resistant variant of community-acquired methicillin-resistant Staphylococcus aureus (MRSA) bacteria is emerging in cities on both coasts of the United States, according to data from a new California-led study.
-
Patients seeking medication abortion using mifepristone (Mifeprex, Danco Group) may be asking questions after news agencies reported leukemia drug safety issues at a Chinese drug manufacturing firm that serves as the sole U.S. supplier of mifepristone.
-
Results of a new survey released by the National Association of Nurse Practitioners in Women's Health (NPWH) indicate that most of the 1,000 women polled often confused myth with fact when quizzed about cervical cancer prevention.
-
Good news for your patients who use oral contraceptives (OCs): A new analysis of 45 epidemiological studies shows that use of such pills during a woman's lifetime gives substantial long-term protection against ovarian cancer.
-
Data released at a recent international conference suggest that adult male circumcision, which has been seen as possibly reducing the risk of HIV transmission in Africa, could raise the risk for women there whose male partners seek the procedure after they are infected.
-
The Food and Drug Administration (FDA) has revised labeling on the contraceptive patch (Ortho Evra, Ortho-McNeil-Janssen Pharmaceuticals; Raritan, NJ) to include new epidemiology data on the risks of venous thromboembolism (VTE).
-
I've Heard of TIA, But What The Heck is a TNA?, Advancing Insulin Therapy in Type 2 Diabetes Previously Treated with Glargine Plus Oral Agents, A Relationship Between Linolenic Acid and Neuropathy in Diabetics
-
The FDA has approved, after priority review, a new non-nucleoside reverse transcriptase inhibitor (NNRTI) for HIV-1 infected adults who have failed other antiretroviral agents.